Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specificMAGE-2 gene product
Marjan J.W. Visseren(Leiden University), W. Martin Kast(University of Southern California), Pierre van der Bruggen(de Duve Institute), Thierry Boon(Ludwig Cancer Research), Cornelis J.M. Melief(ISA Pharmaceuticals (Netherlands)), Ellen I. H. van der Voort(Leiden University), Remco M.P. Brandt(Leiden University), Peter I. Schrier(Leiden University), Sjoerd H. van der Burg(Leiden University Medical Center)
International Journal of Cancer
September 26, 1997
Cited by 56
Related Papers
Therapeutic cancer vaccines
|Journal of Clinical Investigation|2015|1.1k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.
|The Journal of Experimental Medicine|1993|958
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.
|The Journal of Immunology|1994|851
Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells
|European Journal of Immunology|1993|840